Ethionamide

Ethionamide
Clinical data
Trade names	Trecator, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682402
Routes of; administration	by mouth
ATC code	J04AD03 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	~30%
Elimination half-life	2 to 3 hours
Identifiers
	IUPAC name 2-ethylpyridine-4-carbothioamide;
CAS Number	536-33-4 ;
PubChem CID	2761171;
DrugBank	DB00609 ;
ChemSpider	2041901 ;
UNII	OAY8ORS3CQ;
KEGG	D00591 ;
ChEBI	CHEBI:4885 ;
ChEMBL	ChEMBL1441 ;
CompTox Dashboard (EPA)	DTXSID0020577 ;
ECHA InfoCard	100.007.846
Chemical and physical data
Formula	C8H10N2S
Molar mass	166.24 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	164 to 166 °C (327 to 331 °F) (dec.)
	SMILES S=C(c1ccnc(c1)CC)N;
	InChI InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11) ; Key:AEOCXXJPGCBFJA-UHFFFAOYSA-N ;
	(verify)

Ethionamide is an antibiotic used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, to treat active multidrug-resistant tuberculosis. It is no longer recommended for leprosy. It is taken by mouth.

Ethionamide has a high rate of side effects. Common side effects include nausea, diarrhea, abdominal pain, and loss of appetite. Serious side effects may include liver inflammation and depression. It should not be used in people with significant liver problems. Use in pregnancy is not recommended as safety is unclear. Ethionamide is in the thioamides family of medications. It is believed to work by interfering with the use of mycolic acid.

Ethionamide was discovered in 1956 and approved for medical use in the United States in 1965. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.